Rexahn Pharmaceuticals, Inc

(NASDAQ:REXN)

Latest On Rexahn Pharmaceuticals, Inc (REXN):

Date/Time Type Description Signal Details
2020-11-08 00:44 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 16:58 ESTFinancialsCompany financials have been released.Neutral
2020-11-02 18:33 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 13:53 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 06:02 ESTFinancialsCompany financials have been released.Neutral
2020-08-30 05:24 ESTFinancialsCompany financials have been released.Neutral
2020-08-26 13:35 ESTFinancialsCompany financials have been released.Neutral
2020-08-23 01:32 ESTFinancialsCompany financials have been released.Neutral
2020-08-16 18:42 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 09:57 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 21:44 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 13:44 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 17:39 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 05:39 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 13:36 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 18:16 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 09:49 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 17:37 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 13:29 ESTFinancialsCompany financials have been released.Neutral
2020-06-18 23:22 ESTNewsRexahn Pharma up big on announced merger with Ocuphire PharmaN/A
2020-06-14 05:32 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 05:55 ESTFinancialsCompany financials have been released.Neutral
2020-05-27 06:04 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 01:39 ESTFinancialsCompany financials have been released.Neutral
2020-05-10 05:38 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 06:11 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 05:38 ESTFinancialsCompany financials have been released.Neutral
2020-04-12 11:44 ESTNewsRexahn up 76% on RX-0201 license dealN/A
2020-04-12 10:38 ESTNewsRexahn bails on cancer candidate RX-5902 in triple negative breast cancerN/A
2020-04-03 21:39 ESTFinancialsCompany financials have been released.Neutral
2020-03-01 04:23 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 04:51 ESTFinancialsCompany financials have been released.Neutral
2020-02-28 04:51 ESTEarningsEarnings have been released on March 8, 2019, with -$1.08 earnings per share.Buy
2020-02-27 22:23 ESTFinancialsCompany financials have been released.Neutral
2020-02-22 00:34 ESTFinancialsCompany financials have been released.Neutral
2020-02-18 00:20 ESTFinancialsCompany financials have been released.Neutral
2020-02-13 00:35 ESTFinancialsCompany financials have been released.Neutral
2020-02-07 00:40 ESTFinancialsCompany financials have been released.Neutral
2020-02-01 00:37 ESTFinancialsCompany financials have been released.Neutral
2020-01-29 00:33 ESTFinancialsCompany financials have been released.Neutral
2020-01-28 04:55 ESTEarningsEarnings have been released on September 30, 2019, with -$0.49 earnings per share.Buy
2020-01-28 00:38 ESTFinancialsCompany financials have been released.Neutral
2020-01-25 00:25 ESTFinancialsCompany financials have been released.Neutral
2020-01-16 00:40 ESTFinancialsCompany financials have been released.Neutral
2019-12-22 00:13 ESTFinancialsCompany financials have been released.Neutral
2019-12-17 00:27 ESTFinancialsCompany financials have been released.Neutral
2019-11-29 00:14 ESTFinancialsCompany financials have been released.Neutral
2019-11-28 00:25 ESTFinancialsCompany financials have been released.Neutral
2019-11-27 00:25 ESTFinancialsCompany financials have been released.Neutral
2019-11-16 00:26 ESTFinancialsCompany financials have been released.Neutral

About Rexahn Pharmaceuticals, Inc (REXN):

As of November 5, 2020, Rexahn Pharmaceuticals, Inc. was acquired by Ocuphire Pharma, Inc., in a reverse merger transaction. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.

REXN Quotes by TradingView

See Advanced Chart

General

  • Name Rexahn Pharmaceuticals, Inc
  • Symbol REXN
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 5
  • Last Split Factor1:12
  • Last Split Date2019-04-12
  • Fiscal Year EndDecember
  • IPO Date2005-05-23
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.rexahn.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 6.41
  • Price/Book (Most Recent Quarter) 1.42
  • Enterprise Value Revenue 0.12
  • Enterprise Value EBITDA 0.02
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Operating Margin -559%
  • Return on Assets -34%
  • Revenue 1.15 million
  • Earnings Per Share -$4.83
  • Revenue Per Share $0.28
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 2.03 million
  • EBITDA -16533446
  • Analyst Target Price $3
  • Book Value Per Share $2.93
View More

Share Statistics

  • Shares Outstanding 4.48 million
  • Shares Float 4.01 million
  • % Held by Insiders 22%
  • % Held by Institutions 8.33%
  • Shares Short 13595
  • Shares Short Prior Month 2963
  • Short Ratio 0.05
View More

Technicals

  • Beta 0.97
  • 52 Week High $8.45
  • 52 Week Low $1.26
  • 50 Day Moving Average 7.9
  • 200 Day Moving Average 9.37
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
View More

Rexahn Pharmaceuticals, Inc (REXN) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Rexahn Pharmaceuticals, Inc (REXN) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-06-302020-08-10$N/A-$0.62
2020-03-312020-05-18$N/A-$0.15
2019-12-312020-02-21$N/A-$0.46
2019-09-302019-11-06$N/A-$0.49-$0.549.26%
2019-06-302019-08-07$N/A-$0.61-$0.8528.24%
2019-03-312019-05-10$N/A-$0.62-$0.9333.33%
2018-12-312019-03-07$N/A-$1.08-$1.5630.77%
2018-09-302018-11-02$N/A-$2.04-$2.040%
2018-06-302018-08-03$N/A-$1.44-$2.1934.25%
2018-03-312018-05-04-$0.84-$1.6850%
2017-12-312018-03-09-$1.08-$1.6434.15%
2017-09-302017-11-03-$0.48-$2.5681.25%
2017-06-302017-08-04$0.36-$2.52114.29%
2017-03-312017-05-04-$10.80-$2.00-440%
2016-12-312017-02-24$0.10-$0.25140%
2016-09-302016-11-04$N/A-$0.10-$0.2050%
2016-06-302016-08-08$N/A-$0.10-$0.2050%
2016-03-312016-05-09$N/A-$0.20-$0.200%
2015-12-312016-03-14-$0.20-$0.2520%
2015-09-302015-11-02$N/A-$0.20-$0.3339.39%
2015-06-302015-08-07$N/A-$0.20-$0.2725.93%
2015-03-312015-05-08$N/A-$0.02-$0.0333.33%
2014-12-312015-03-17-$0.02-$0.020%
2014-09-302014-11-12$N/A-$0.01-$0.0250%
2014-06-302014-08-13$N/A$0.13-$2.40105.47%
2014-03-312014-05-14$N/A-$10.80-$2.40-350%
2013-12-312014-03-21-$1.20-$3.6066.67%
2013-09-302013-11-14-$2.40-$1.80-33.33%
2013-06-302013-08-28-$3.12
2013-03-312013-05-09-$1.20-$2.4050%
2012-12-312013-03-22-$0.06-$2.4097.68%
2012-09-302012-11-28-$3.76
2012-06-302012-08-29-$1.31
2012-03-312012-05-30-$2.69
2011-12-312012-03-16$1.20-$4.80125%
2011-09-302011-11-09-$1.20-$9.6087.5%
2011-06-302011-08-09-$7.20-$7.200%
2011-03-312011-05-09-$6.00-$4.80-25%
2010-12-312011-03-16-$3.60-$3.600%
2010-09-302010-12-01-$3.35
2010-06-302010-09-01-$5.02
2010-03-312010-06-02-$2.61
2009-12-312010-03-31-$2.40-$3.6033.33%
2009-09-302009-11-16-$2.40-$3.6033.33%
2009-06-302009-09-02-$3.68
2009-03-312009-06-03-$3.18
2008-12-312008-12-31-$3.54
2008-09-302008-09-30-$2.60
2008-06-302008-06-30-$1.60
2008-03-312008-03-31-$2.83
2007-12-312007-12-31-$2.14
2007-09-302007-09-30-$2.48
2007-06-302007-06-30-$2.82
2007-03-312007-03-31-$2.83
2006-12-312006-12-31-$1.43
2006-09-302006-09-30-$4.08
2006-06-302006-06-30-$3.72
2006-03-312006-03-31-$6.92
2005-12-312005-12-31-$8.40
2005-09-302005-09-30-$3.20
2005-06-302005-06-30-$3.74
2005-03-312005-03-31-$240.01
2004-12-312004-12-31-$4,440.18

Rexahn Pharmaceuticals, Inc (REXN) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development N/A N/A N/A 454727 1.13 million
Income Before Tax N/A N/A N/A -1.87 million -1.96 million
Selling General Administrative N/A N/A N/A 1.55 million 1.15 million
Gross Profit N/A N/A N/A N/A N/A
Ebit N/A N/A N/A -2.01 million -2.28 million
Operating Income N/A N/A N/A -2.01 million -2.28 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A 139286 321394
Net Income From Continuing Operations N/A N/A N/A -1.87 million -1.96 million
Net Income Applicable to Common Shares -1.4 million -2.51 million -586770 -1.87 million -1.96 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A 3 million 3 million
Change to Liabilities 67728 1 million -928724 -100484 -554519
Total Cash Flow from Investing Activities N/A N/A 3 million 3 million 3 million
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A N/A
Change to Operating Activities 241569 -528707 154958 273520 309333
Change in Cash N/A N/A N/A 1.29 million 622051
Total Cash from Operating Activities -1.13 million -1.79 million -1.22 million -1.71 million -2.38 million
Depreciation N/A N/A N/A 9532 9383
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income -43796 237771 129830 -26197 -182916
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities N/A N/A N/A 3.01 million 3.23 million
Total Stockholder Equity N/A N/A N/A 9.96 million 11.76 million
Other Current Liabilities 650000 N/A N/A 1.5 million 1.5 million
Total Assets N/A N/A N/A 12.97 million 14.98 million
Common Stock 448 402 402 402 402
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -167.82 million -166.42 million -163.91 million -163.32 million -161.45 million
Other Liabilities 110781 268811 100109 41717 123872
Other Assets 25681 25681 25681 25681 25681
Cash N/A N/A N/A 9.22 million 7.93 million
Total Current Liabilities 3.01 million N/A N/A 2.91 million 3 million
Other Stockholder Equity N/A N/A N/A 2084 7848
Property, Plant & Equipment 154883 196789 238385 279118 319238
Total Current Assets 8.65 million N/A N/A 12.66 million 14.64 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 5.71 million 7 million 9.45 million 9.96 million 11.76 million
Short Term Investments N/A N/A N/A 3 million 5.98 million
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 2.26 million N/A N/A 488285 1.37 million

Rexahn Pharmaceuticals, Inc (REXN) Chart:

Rexahn Pharmaceuticals, Inc (REXN) News:

Below you will find a list of latest news for Rexahn Pharmaceuticals, Inc (REXN) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Rexahn Pharmaceuticals, Inc (REXN) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Rexahn Pharmaceuticals, Inc (REXN) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120015244/0001140361-20-015244-index.htm
2018-07-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1228627/000000000018021523/0000000000-18-021523-index.htm
2018-07-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1228627/000000000018022160/0000000000-18-022160-index.htm
2019-07-12UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1228627/000000000019011080/0000000000-19-011080-index.htm
2019-10-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1228627/000000000019014362/0000000000-19-014362-index.htm
2019-02-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1228627/000091957419000760/0000919574-19-000760-index.htm
2020-08-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1228627/000091957420004951/0000919574-20-004951-index.htm
2018-10-26SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1228627/000110465918064080/0001104659-18-064080-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1228627/000110465919008566/0001104659-19-008566-index.htm
2018-06-18DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1228627/000114036118029005/0001140361-18-029005-index.htm
2018-06-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036118030409/0001140361-18-030409-index.htm
2018-06-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1228627/000114036118030411/0001140361-18-030411-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036118030725/0001140361-18-030725-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036118030728/0001140361-18-030728-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036118030732/0001140361-18-030732-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036118030736/0001140361-18-030736-index.htm
2018-07-09PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1228627/000114036118031931/0001140361-18-031931-index.htm
2018-07-18CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1228627/000114036118032806/0001140361-18-032806-index.htm
2018-07-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1228627/000114036118033155/0001140361-18-033155-index.htm
2018-08-0310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1228627/000114036118035394/0001140361-18-035394-index.htm
2018-08-07DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1228627/000114036118035693/0001140361-18-035693-index.htm
2018-08-07DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1228627/000114036118035696/0001140361-18-035696-index.htm
2018-08-09DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1228627/000114036118036069/0001140361-18-036069-index.htm
2018-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036118036732/0001140361-18-036732-index.htm
2018-08-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1228627/000114036118036803/0001140361-18-036803-index.htm
2018-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036118037339/0001140361-18-037339-index.htm
2018-10-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1228627/000114036118040882/0001140361-18-040882-index.htm
2018-10-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036118040906/0001140361-18-040906-index.htm
2018-11-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1228627/000114036118042255/0001140361-18-042255-index.htm
2018-11-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036118043281/0001140361-18-043281-index.htm
2018-11-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036118043286/0001140361-18-043286-index.htm
2018-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036118044418/0001140361-18-044418-index.htm
2018-12-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036118044424/0001140361-18-044424-index.htm
2018-12-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036118044426/0001140361-18-044426-index.htm
2019-01-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1228627/000114036119001360/0001140361-19-001360-index.htm
2019-01-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119001362/0001140361-19-001362-index.htm
2019-01-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1228627/000114036119001517/0001140361-19-001517-index.htm
2019-01-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119001600/0001140361-19-001600-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119001633/0001140361-19-001633-index.htm
2019-01-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119001635/0001140361-19-001635-index.htm
2019-01-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119001802/0001140361-19-001802-index.htm
2019-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119002080/0001140361-19-002080-index.htm
2019-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119002082/0001140361-19-002082-index.htm
2019-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119002419/0001140361-19-002419-index.htm
2019-02-04PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119002426/0001140361-19-002426-index.htm
2019-02-14DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119003255/0001140361-19-003255-index.htm
2019-03-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119004259/0001140361-19-004259-index.htm
2019-03-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119004269/0001140361-19-004269-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119004271/0001140361-19-004271-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119004274/0001140361-19-004274-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119004276/0001140361-19-004276-index.htm
2019-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119004489/0001140361-19-004489-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1228627/000114036119004539/0001140361-19-004539-index.htm
2019-03-11DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1228627/000114036119004632/0001140361-19-004632-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119004634/0001140361-19-004634-index.htm
2019-04-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119006977/0001140361-19-006977-index.htm
2019-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119007130/0001140361-19-007130-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119007856/0001140361-19-007856-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1228627/000114036119008945/0001140361-19-008945-index.htm
2019-05-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119009949/0001140361-19-009949-index.htm
2019-06-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119010648/0001140361-19-010648-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119010668/0001140361-19-010668-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119010669/0001140361-19-010669-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119010671/0001140361-19-010671-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119010673/0001140361-19-010673-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119010676/0001140361-19-010676-index.htm
2019-06-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119010678/0001140361-19-010678-index.htm
2019-06-0725Notification of the removal from listing and registration of matured, redeemed or retired securitieshttps://www.sec.gov/Archives/edgar/data/1228627/000114036119010682/0001140361-19-010682-index.htm
2019-06-078-A12BRegistration of securities [Section 12(b)]https://www.sec.gov/Archives/edgar/data/1228627/000114036119010684/0001140361-19-010684-index.htm
2019-07-26CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1228627/000114036119013497/0001140361-19-013497-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119014411/0001140361-19-014411-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1228627/000114036119014413/0001140361-19-014413-index.htm
2019-08-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119015750/0001140361-19-015750-index.htm
2019-08-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036119015801/0001140361-19-015801-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1228627/000114036119019932/0001140361-19-019932-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120002721/0001140361-20-002721-index.htm
2020-02-2110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1228627/000114036120003785/0001140361-20-003785-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120005875/0001140361-20-005875-index.htm
2020-04-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120008410/0001140361-20-008410-index.htm
2020-04-2910-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1228627/000114036120010048/0001140361-20-010048-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1228627/000114036120010906/0001140361-20-010906-index.htm
2020-06-18425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120014136/0001140361-20-014136-index.htm
2020-06-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120014267/0001140361-20-014267-index.htm
2020-06-19425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120014268/0001140361-20-014268-index.htm
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120015244/0001140361-20-015244-index.htm
2020-07-01425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120015245/0001140361-20-015245-index.htm
2020-07-06S-4Registration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120015421/0001140361-20-015421-index.htm
2020-08-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120017238/0001140361-20-017238-index.htm
2020-08-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1228627/000114036120018406/0001140361-20-018406-index.htm
2020-08-27S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120019177/0001140361-20-019177-index.htm
2020-09-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120019615/0001140361-20-019615-index.htm
2020-09-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120020176/0001140361-20-020176-index.htm
2020-09-16S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120020569/0001140361-20-020569-index.htm
2020-09-30S-4/ARegistration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120021938/0001140361-20-021938-index.htm
2020-10-02424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1228627/000114036120022250/0001140361-20-022250-index.htm
2020-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120022798/0001140361-20-022798-index.htm
2020-10-09425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120022799/0001140361-20-022799-index.htm
2020-10-16425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120023152/0001140361-20-023152-index.htm
2020-10-20425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120023372/0001140361-20-023372-index.htm
2020-10-2910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1228627/000114036120024042/0001140361-20-024042-index.htm
2020-11-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120024376/0001140361-20-024376-index.htm
2020-11-03425Prospectuses and communications, business combinationshttps://www.sec.gov/Archives/edgar/data/1228627/000114036120024377/0001140361-20-024377-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000114036120024749/0001140361-20-024749-index.htm
2018-10-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1228627/000119312518310598/0001193125-18-310598-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1228627/000119312519040135/0001193125-19-040135-index.htm
2019-06-10CERTCertificationhttps://www.sec.gov/Archives/edgar/data/1228627/000135445719000304/0001354457-19-000304-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1228627/000156761919007648/0001567619-19-007648-index.htm
2020-10-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1228627/999999999520002720/9999999995-20-002720-index.htm
2018-12-17CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1228627/999999999718009562/9999999997-18-009562-index.htm
2019-08-15SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1228627/999999999719006516/9999999997-19-006516-index.htm
2019-10-07SEC STAFF SEC Staff Letter: REDACTED EXHIBIThttps://www.sec.gov/Archives/edgar/data/1228627/999999999719007242/9999999997-19-007242-index.htm

Rexahn Pharmaceuticals, Inc (REXN) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rexahn Pharmaceuticals, Inc (REXN). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 22%
Institutional Ownership: 833%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-01-31Charles BeeverDirectorBuy10,000.000.646,380.0011,000.00https://www.sec.gov/Archives/edgar/data/1228627/000114036119002419/0001140361-19-002419-index.htm
2019-01-29Ben Gil PriceDirectorBuy15,000.000.619,141.0015,000.00https://www.sec.gov/Archives/edgar/data/1228627/000114036119002082/0001140361-19-002082-index.htm
2019-01-30Lisa NolanChief Business OfficerBuy20,000.000.6512,960.0021,625.00https://www.sec.gov/Archives/edgar/data/1228627/000114036119002080/0001140361-19-002080-index.htm
2019-02-28Lisa NolanChief Business OfficerBuy1,625.0023,250.00https://www.sec.gov/Archives/edgar/data/1228627/000114036119004276/0001140361-19-004276-index.htm
2019-02-28Ely BenaimChief Medical OfficerBuy2,375.004,750.00https://www.sec.gov/Archives/edgar/data/1228627/000114036119004274/0001140361-19-004274-index.htm
2019-01-29Douglas J SwirskyPresident and CEOBuy50,000.000.6331,720.0050,000.00https://www.sec.gov/Archives/edgar/data/1228627/000114036119001802/0001140361-19-001802-index.htm